Status:
COMPLETED
Accelerated Versus Standard CXL in the Treatment of Ectasia Post Refractive Surgery and Penetrating Keratoplasty.
Lead Sponsor:
Menoufia University
Conditions:
Refractive Surgery
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
WHAT WAS KNOWN \*Standard CXL is the common procedure for treating progressive corneal ectasia. Modifications of the standard protocol were introduces to reduce its complications especially long expo...
Detailed Description
Purpose: The aim of this study is to compare the clinical outcomes of the Standard CXL and the AC CXL in patients with progressive corneal ectasia post refractive surgery and penetrating keratoplasty...
Eligibility Criteria
Inclusion
- Eligible patients were:
- adults aged above 18 years.
- They have been diagnosed clinically with progressive corneal ectasia following refractive surgery procedure (LASIK, PRK, ReLex smile), or penetrating keratoplasty
- CCT above 400µ.
Exclusion
- The exclusion criteria involved:
- history of herpetic ocular diseases (including herpes simplex virus and varicella zoster virus) in the study eye
- active or recurrent ocular disease in either eye (e.g., uveitis, chronic moderate to severe blepharitis or severe dry eye) or sight-threatening diseases (e.g., previous retinal or optic nerve diseases) that would interfere with the interpretation of the study data.
Key Trial Info
Start Date :
January 16 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 26 2017
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT03791684
Start Date
January 16 2016
End Date
June 26 2017
Last Update
January 4 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.